Status:
COMPLETED
Systematic Evaluation by an Intensivist of Hematological Malignancy Patients Presenting With Acute Respiratory or Hemodynamic Failure
Lead Sponsor:
University Hospital, Grenoble
Conditions:
Respiratory Insufficiency
Hematologic Malignancy
Eligibility:
All Genders
18+ years
Brief Summary
Over the last two decades, the number of patients with hematological malignancies (HMs) admitted to the ICU increased and their mortality has dropped sharply. Patients with HMs increasingly require ad...
Eligibility Criteria
Inclusion
- Patients hospitalized in a hematology unit
- Patients presenting with criteria for critical respiratory and/or hemodynamic condition and worsening during the next 4 hours
- Respiratory : oxygen saturation \<90 % and/or O2 \>3l/min, with either a worsening of saturation or increased oxygen needs within 4h
- Hemodynamic : systolic blood pressure \< 90 mmHg and remaining \< 90 mmHg within 4h despite ≥ 1l of crystalloid administration, or becoming \< 80 mmHg no matter the quantity of fluid (even if no fluid administration).
Exclusion
- therapeutic limitations decided hematological investigators (moribund patients, uncontrolled allogenic graft,...)
- Do-not-reanimate directives
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
February 13 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2020
Estimated Enrollment :
221 Patients enrolled
Trial Details
Trial ID
NCT03399149
Start Date
February 13 2017
End Date
March 1 2020
Last Update
November 7 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematologic unit - Hospital Grenoble Alpes
Grenoble, France
2
Intensive Care Unit - Hospital Grenoble-Alpes
Grenoble, France